The private label CBD gummies market is poised for substantial growth, with Future Market Insights (FMI) projecting it to reach USD 1,382.2 million by 2036, up from USD 646.2 million in 2026, at a compound annual growth rate (CAGR) of 7.9%. This expansion is fueled by wellness brands increasingly adopting outsourced manufacturing to enter the CBD edibles market without heavy capital investment in extraction or confectionery facilities.
According to FMI, the market was valued at USD 598.9 million in 2025. Key drivers include the growing preference for ready-to-market CBD edible products and the rising adoption of white label production models, which reduce launch costs and shorten commercialization timelines. White label gummies are expected to dominate the service model segment, accounting for 46.2% of global demand in 2026, due to their shorter timelines and lower formulation costs.
Broad-spectrum CBD gummies are forecast to lead the CBD spectrum segment with a 42.8% market share in 2026, driven by consumer demand for THC-free wellness products that retain multiple cannabinoids. Brand websites are the leading sales channel, representing 39.6% of demand, as they offer greater control over customer education, subscription programs, and repeat purchasing.
Nandini Roy Choudhury, Principal Consultant for Food & Beverage at FMI, stated: "Private label CBD gummies provide wellness brands with a faster and more efficient route into the expanding CBD edibles market. Going forward, competitive advantage will increasingly depend on suppliers that combine formulation expertise with comprehensive testing, compliant labeling, and retail-ready documentation."
Geographically, the United States is the fastest-growing market, with a projected CAGR of 8.5% through 2036, supported by a strong direct-to-consumer infrastructure and a mature contract manufacturing ecosystem. Other key markets include Canada (8.1% CAGR), the United Kingdom (7.8%), Germany (7.5%), and Australia (7.3%).
Major players in the market include CBD Nationwide, Extract Labs, cbdMD, Inc., Charlotte's Web Holdings, Inc., CV Sciences, Inc., Medterra CBD LLC, British Cannabis, Cannaray Limited, MediPharm Labs Corp., and Little Green Pharma Ltd. These companies compete on formulation expertise, manufacturing scalability, compliance support, and packaging capabilities.
The market faces challenges such as regulatory complexity surrounding CBD health claims and labeling requirements, which can delay commercialization and increase costs. However, trends like white label manufacturing, broad-spectrum formulations, third-party testing, and subscription-based direct-to-consumer models are driving growth. For more detailed insights, refer to the full report at FMI's sample report.
FMI's custom research solutions offer tailored strategic intelligence to help businesses navigate regulatory frameworks, consumer preferences, and competitive dynamics. With over 100 analysts and 20,000+ published reports, FMI supports informed decision-making in the evolving wellness landscape.
